Piddock Laura J V, Johnson M M, Webber Mark A
Antimicrobial Agents Research Group, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, UK.
J Antimicrob Chemother. 2003 Sep;52(3):500-2. doi: 10.1093/jac/dkg373. Epub 2003 Aug 13.
To determine whether an association exists between ciprofloxacin and faropenem resistance in bacteria including multiply drug-resistant isolates.
The MICs were determined for 150 fluoroquinolone-resistant bacteria, plus 20 nalidixic acid-resistant strains of Salmonella enterica serovar Typhimurium.
Faropenem was very active against Escherichia coli and Streptococcus pneumoniae, but 5/31 Staphylococcus aureus and 2/26 Bacteroides fragilis required > or =16 mg/L for inhibition. Of 30 multiply drug-resistant isolates with a phenotype suggestive of enhanced efflux, only for one strain (a Bacteroides fragilis) was the faropenem MIC higher than that associated with the other isolates of the same species.
Faropenem was in general as active as imipenem. There was no association between resistance to ciprofloxacin and faropenem or imipenem resistance.